SCStefano Cucuzza

Stefano Cucuzza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stefano Cucuzza has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Simplified kinetic modeling for predicting the stability of complex biotherapeutics

    by Mitja Zidar, Stefano Cucuzza, Matjaž Bončina, Drago Kuzman

    Stability studies are vital in biologics development, guiding formulation, packaging, and shelf life determination. Traditionally, predicting long-term stability based on short-term data has been challenging due to the complex behavior of biologics. However, recently have been demonstrated that by using simple kinetics and the Arrhenius equation, it is possible to achieve accurate long-term stability predictions for various quality attributes, including protein aggregates. This study focuses on effective modeling of aggregate predictions for diverse protein modalities, such as IgG1, IgG2, Bispecific IgG, Fc fusion, scFv, bivalent nanobodies, and DARPins, using a first-order kinetic model. Notably, findings highlight the significance of temperature selection in stability studies, enabling the identification of dominant degradation processes. Additionally, simplicity of the first-order kinetic model enhances reliability by reducing the number of parameters and samples required. The model’s effectiveness was further validated across various protein formats, beyond IgG, emphasizing its broad applicability and reliability. Compared to linear extrapolation, the kinetic model provided more precise and accurate stability estimates, even with limited data points. These findings highlight the benefits of using kinetic modeling with optimal temperature selection to predict protein aggregate stability and other quality attributes, aiding biologics development and shelf-life determination.


  • Modular and tunable alternative surfactants for biopharmaceuticals provide insights into Surfactant’s Structure-Function relationship

    by Stefano Cucuzza, Sebastian Brosig, Tim Serno, Karoline Bechtold-Peters, Jure Cerar, Michael Kammüller, Fabrice Gallou


  • Not the Usual Suspects: Alternative Surfactants for Biopharmaceuticals

    by Sebastian Brosig, Stefano Cucuzza, Tim Serno, Karoline Bechtold-Peters, Jakob Buecheler, Matej Zivec, Oliver Germershaus, Fabrice Gallou

    Therapeutically relevant proteins naturally adsorb to interfaces, causing aggregation which in turn potentially leads to numerous adverse consequences such as loss of activity or unwanted immunogenic reactions. Surfactants are ubiquitously used in biotherapeutics drug development to oppose interfacial stress, yet, the choice of the surfactant is extremely limited: to date, only polysorbates (PS20/80) and poloxamer 188 are used in commercial products. However, both surfactant families suffer from severe degradation and impurities of the raw material, which frequently increases the risk of particle generation, chemical protein degradation, and potential adverse immune reactions. Herein, we assessed a total of 40 suitable alternative surfactant candidates and subsequently performed a selection through a three-gate screening process employing four protein modalities encompassing six different formulations. The screening is based on short-term agitation-induced aggregation studies coupled to particle analysis and surface tension characterization, followed by long-term quiescence stability studies connected to protein purity measurements and particle analysis. The study concludes by assessing the surfactant's chemical and enzymatic degradation propensity. The candidates emerging from the screening are de novo α-tocopherol-derivatives named VEDG-2.2 and VEDS, produced ad hoc for this study. They display protein stabilization potential comparable or better than polysorbates together with an increased resistance to chemical and enzymatic degradation, thus representing valuable alternative surfactants for biotherapeutics.


  • Open Access

    Correction to: An automated iterative approach for protein structure refinement using pseudocontact shifts

    by Stefano Cucuzza, Peter Güntert, Andreas Plückthun, Oliver Zerbe

  • Open Access

    An automated iterative approach for protein structure refinement using pseudocontact shifts

    by Stefano Cucuzza, Peter Güntert, Andreas Plückthun, Oliver Zerbe

    NMR structure calculation using NOE-derived distance restraints requires a considerable number of assignments of both backbone and sidechains resonances, often difficult or impossible to get for large or complex proteins. Pseudocontact shifts (PCSs) also play a well-established role in NMR protein structure calculation, usually to augment existing structural, mostly NOE-derived, information. Existing refinement protocols using PCSs usually either require a sizeable number of sidechain assignments or are complemented by other experimental restraints. Here, we present an automated iterative procedure to perform backbone protein structure refinements requiring only a limited amount of backbone amide PCSs. Already known structural features from a starting homology model, in this case modules of repeat proteins, are framed into a scaffold that is subsequently refined by experimental PCSs. The method produces reliable indicators that can be monitored to judge about the performance. We applied it to a system in which sidechain assignments are hardly possible, designed Armadillo repeat proteins (dArmRPs), and we calculated the solution NMR structure of YM4A, a dArmRP containing four sequence-identical internal modules, obtaining high convergence to a single structure. We suggest that this approach is particularly useful when approximate folds are known from other techniques, such as X-ray crystallography, while avoiding inherent artefacts due to, for instance, crystal packing.


  • Open Access

    The novel influenza A virus protein PA-X and its naturally deleted variant show different enzymatic properties in comparison to the viral endonuclease PA

    by Laura Bavagnoli, Stefano Cucuzza, Giulia Campanini, Francesca Rovida, Stefania Paolucci, Fausto Baldanti, Giovanni Maga

    The PA protein of Influenza A virus (IAV) encoded by segment 3 acts as a specialized RNA endonuclease in the transcription of the viral genome. The same genomic segment encodes for a second shorter protein, termed PA-X, with the first 191 N-terminal aminoacids (aa) identical to PA, but with a completely different C-ter domain of 61 aa, due to a ribosomal frameshifting. In addition, it has been shown that several IAV isolates encode for a naturally truncated PA-X variant, PAXΔC20, missing the last 20 aa. The biochemical properties of PA-X and PAXΔC20 have been poorly investigated so far. Here, we have carried out an enzymatic characterization of PA-X and its naturally deleted form, in comparison with PA from the human IAV strain A/WSN/33 (H1N1). Our results showed, to the best of our knowledge for the first time, that PA-X possesses an endonucleolytic activity. Both PA and PA-X preferentially cut single stranded RNA regions, but with some differences. In addition, we showed that PAXΔC20 has severely reduced nuclease activity. These results point to a previously undetected role of the last C-ter 20 aa for the catalytic activity of PA-X and support distinct roles for these proteins in the viral life cycle.